| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the UCSF/Mt. Zion Multiple Sclerosis Center (Drs. Waubant, Goodkin, and Andersson, and R. Sloan and T. Stewart), San Francisco, CA; the Department of Epidemiology and Biostatistics (L. Gee and Dr. Bacchetti), University of California, San Francisco; and British Biotech (G. Stabler and Dr. Miller), Oxford, UK.
Address correspondence and reprint requests to Dr. Emmanuelle Waubant, UCSF/Mt. Zion Multiple Sclerosis Center, 1701 Divisadero Street, San Francisco, CA 94115.
OBJECTIVE: To 1) compare monthly serum levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of MMP-type 1 (TIMP-1) in patients with relapsing-remitting MS (RRMS) versus healthy controls and 2) determine the relationship among monthly serum levels of MMP-9 and TIMP-1 and MRI activity.
BACKGROUND: Activated T-cells and macrophages secrete MMPs that may facilitate their migration across vascular subendothelial basement membranes into the CNS. The serum concentration of MMP-9 is reported to be higher in patients with RRMS than healthy controls.
METHODS: Monthly evaluations including gadolinium-enhanced (Gd+) brain MRI and measures of serum MMP-9 and TIMP-1 were performed for up to 15 months in 24 patients with RRMS and for up to 4 months in 10 controls.
RESULTS: Serum MMP-9 but not TIMP-1 levels are elevated in RRMS patients compared to healthy controls (p = 0.025, p = 0.61). In a univariate analysis, high MMP-9 and low TIMP-1 levels precede appearance of new Gd+ lesions (respectively; odds ratio = 3.3, p = 0.008; odds ratio = 2.2, p = 0.086). In a multivariate analysis, in comparison to months when MMP-9 is low and TIMP-1 high, MRI scans obtained the month following high MMP-9 and low TIMP-1 serum concentrations are more likely to report new Gd+ lesions (p = 0.0006, odds ratio = 21.5).
CONCLUSION: An increase in the activity of matrix metalloproteinase-9 (MMP-9) relative to tissue inhibitor of MMP-type 1 (TIMP-1) may be related to formation of new MS lesions, suggesting that serum levels of MMP-9 and TIMP-1 may be surrogate markers of disease activity in relapsing-remitting MS.
Key words: Matrix metalloproteinase—Inhibitor of metalloproteinase—MS—MRI.
This article has been cited by other articles:
|
|
 |
|
  Y. Benesova Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis Multiple Sclerosis, November 1, 2009; 15(11): 1374 - 1375. [PDF]
|
|
|
|
 |
|
 H. Li, A. Mittal, D. Y. Makonchuk, S. Bhatnagar, and A. Kumar Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy Hum. Mol. Genet., July 15, 2009; 18(14): 2584 - 2598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y Benesova, A Vasku, H Novotna, J Litzman, P Stourac, M Beranek, Z Kadanka, and J Bednarik Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis Multiple Sclerosis, March 1, 2009; 15(3): 316 - 322. [Abstract] [PDF]
|
|
|
|
 |
|
 A. E. Cardona, M. Li, L. Liu, C. Savarin, and R. M. Ransohoff Chemokines in and out of the central nervous system: much more than chemotaxis and inflammation J. Leukoc. Biol., September 1, 2008; 84(3): 587 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sellner, I. Greeve, S. L. Leib, and H. P. Mattle Atorvastatin Does Not Alter Interferon Beta-Induced Changes of Serum Matrix Metalloproteinase 9 and Tissue Inhibitor of Metalloproteinase 1 in Patients With Multiple Sclerosis Arch Neurol, May 1, 2008; 65(5): 672 - 674. [Full Text] [PDF]
|
|
|
|
|
|
A. Minagar, J. S. Alexander, R. N. Schwendimann, R. E. Kelley, E. Gonzalez-Toledo, J. J. Jimenez, L. Mauro, W. Jy, and S. J. Smith Combination Therapy With Interferon Beta-1a and Doxycycline in Multiple Sclerosis: An Open-Label Trial Arch Neurol, February 1, 2008; 65(2): 199 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Mannello, G.A.M. Tonti, and F. Canestrari The `never-ending story' of the influence of blood specimen collection methods affecting the concentration, the zymographic profile and the usefulness of matrix metalloproteinases and their tissue inhibitors in multiple sclerosis diagnosis/prognosis: a landmark for limiting the misuse of serum samples Multiple Sclerosis, June 1, 2007; 13(5): 687 - 690. [PDF]
|
|
|
|
 |
|
 S. Dhib-Jalbut Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis Neurology, May 29, 2007; 68(22_suppl_3): S13 - S21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Fainardi, M Castellazzi, T Bellini, M C Manfrinato, E Baldi, I Casetta, E Paolino, E Granieri, and F Dallocchio Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis Multiple Sclerosis, June 1, 2006; 12(3): 294 - 301. [Abstract] [PDF]
|
|
|
|
|
|
R P Lisak, J A Benjamins, B Bealmear, B Yao, S Land, L Nedelkoska, and D Skundric Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for immune-related molecules by central nervous system mixed glial cell cultures Multiple Sclerosis, April 1, 2006; 12(2): 149 - 168. [Abstract] [PDF]
|
|
|
|
 |
|
 T Kanesaka, M Mori, T Hattori, T Oki, and S Kuwabara Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis J. Neurol. Neurosurg. Psychiatry, February 1, 2006; 77(2): 185 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Avolio, M Filippi, C Tortorella, M A Rocca, M Ruggieri, F Agosta, V Tomassini, C Pozzilli, S Stecchi, P Giaquinto, et al. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment Multiple Sclerosis, August 1, 2005; 11(4): 441 - 446. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Zhou, N. W. Marten, C. C. Bergmann, W. B. Macklin, D. R. Hinton, and S. A. Stohlman Expression of Matrix Metalloproteinases and Their Tissue Inhibitor during Viral Encephalitis J. Virol., April 15, 2005; 79(8): 4764 - 4773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V Yadav, G Marracci, J Lovera, W Woodward, K Bogardus, W Marquardt, L Shinto, C Morris, and D Bourdette Lipoic acid in multiple sclerosis: a pilot study Multiple Sclerosis, April 1, 2005; 11(2): 159 - 165. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Toft-Hansen, R. K. Nuttall, D. R. Edwards, and T. Owens Key Metalloproteinases Are Expressed by Specific Cell Types in Experimental Autoimmune Encephalomyelitis J. Immunol., October 15, 2004; 173(8): 5209 - 5218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Gilli, A. Bertolotto, A. Sala, F. Hoffmann, M. Capobianco, S. Malucchi, T. Glass, L. Kappos, R. L.P. Lindberg, and D. Leppert Neutralizing antibodies against IFN-{beta} in multiple sclerosis: antagonization of IFN-{beta} mediated suppression of MMPs Brain, February 1, 2004; 127(2): 259 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Minagar and J S. Alexander Blood-brain barrier disruption in multiple sclerosis Multiple Sclerosis, December 1, 2003; 9(6): 540 - 549. [Abstract] [PDF]
|
|
|
|
|
|
E. Waubant, D. Goodkin, A. Bostrom, P. Bacchetti, J. Hietpas, R. Lindberg, and D. Leppert IFN{beta} lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS Neurology, January 14, 2003; 60(1): 52 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Seifert, B C Kieseier, S Ropele, S Strasser-Fuchs, F Quehenberger, F Fazekas, and H-P Hartung TACE mRNA expression in peripheral mononuclear cells precedes new lesions on MRI in multiple sclerosis Multiple Sclerosis, December 1, 2002; 8(6): 447 - 451. [Abstract] [PDF]
|
|
|
|
 |
|
 G. A. Rosenberg Matrix Metalloproteinases and Neuroinflammation in Multiple Sclerosis Neuroscientist, December 1, 2002; 8(6): 586 - 595. [Abstract] [PDF]
|
|
|
|
|
|
V. W. Yong Differential mechanisms of action of interferon-{beta} and glatiramer acetate in MS Neurology, September 24, 2002; 59(6): 802 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G M Liuzzi, M Trojano, M Fanelli, C Avolio, A Fasano, P Livrea, and P Riccio Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis Multiple Sclerosis, June 1, 2002; 8(3): 222 - 228. [Abstract] [PDF]
|
|
|
|
|
|
V. Brundula, N. B. Rewcastle, L. M. Metz, C. C. Bernard, and V. W. Yong Targeting leukocyte MMPs and transmigration: Minocycline as a potential therapy for multiple sclerosis Brain, June 1, 2002; 125(6): 1297 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dhib-Jalbut Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis Neurology, April 23, 2002; 58(90084): S3 - 9. [Abstract] [Full Text]
|
|
|
|
|
|
Z. Ma, H. Qin, and E. N. Benveniste Transcriptional Suppression of Matrix Metalloproteinase-9 Gene Expression by IFN-{gamma} and IFN-{beta}: Critical Role of STAT-1{alpha} J. Immunol., November 1, 2001; 167(9): 5150 - 5159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. P. Lindberg, C. J. A. De Groot, L. Montagne, P. Freitag, P. van der Valk, L. Kappos, and D. Leppert The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis Brain, September 1, 2001; 124(9): 1743 - 1753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Mandler, J. D. Dencoff, F. Midani, C. C. Ford, W. Ahmed, and G. A. Rosenberg Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic's neuromyelitis optica Brain, March 1, 2001; 124(3): 493 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. T. Bever Jr. and G. A. Rosenberg Matrix metalloproteinases in multiple sclerosis Neurology, October 22, 1999; 53(7): 1380 - 1380. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
